Oruka Therapeutics
Oruka Therapeutics Inc is an American biotechnology enterprise focused on developing novel biologic therapies for chronic skin and inflammatory diseases. The company designs engineered monoclonal antibodies targeting validated cytokines, with a focus on delivering extended durability and convenient dosing regimens. Its key pipeline programs include ORKA-001, an interleukin-23 inhibitor, and ORKA-002, an interleukin-17 inhibitor designed for plaque psoriasis and related conditions. Operations revolve around preclinical asset optimization, protein engineering, bio-manufacturing, and clinical development management. As a development-stage biopharmaceutical entity, Oruka generates minimal commercial revenue and finances its operations through capital markets and private equity backing. The company holds an emerging position in targeted immunological therapies. Oruka Therapeutics is headquartered in Menlo Park, California, United States, and its common stock is traded on the Nasdaq Global Market.
10 of the funds FundTelligence covers report a position in Oruka Therapeutics.
- Legal name
- ORUKA THERAPEUTICS INC
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 10
Funds holding Oruka Therapeutics
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 2.2 % (full portfolio disclosed, September 2026)
- DNB Bioteknologi — DNB · 1.34 % (full portfolio disclosed, September 2026)
- SEB Läkemedelsfond — SEB · 1.04 % (full portfolio disclosed, June 2026)
- JPM US Small Cap Growth Fund — JPM · 0.91 % (full portfolio disclosed, June 2026)
- Handelsbanken Amerika SMB Tema — Handelsbanken · 0.49 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.44 % (full portfolio disclosed, October 2026)
- Handelsbanken Helse Tema — Handelsbanken · 0.36 % (full portfolio disclosed, October 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.22 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 10 funds holding it.